Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is now covered by analysts at Scotiabank. They set a "sector outperform" rating and a $15.00 price target on the stock.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Aclaris Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Aclaris Therapeutics to Participate in Two March Healthcare Conferences [Yahoo! Finance]